



Market Announcement

12 September 2022

Imugene Limited (ASX: IMU) – Trading Halt

Description

The securities of Imugene Limited ('IMU') will be placed in trading halt at the request of IMU, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 14 September 2022 or when the announcement is released to the market.

Issued by

Melissa Kostopoulos

Compliance Adviser, Listings Compliance (Melbourne)



IMUGENE

Developing Cancer Immunotherapies
Suite 12.01, Level 12
4-6 Blich Street
Sydney NSW 2000
www.imugene.com
ABN: 99 009 179 551
Phone: +61 3 9824 5254

12 September 2022

Melissa Kostopoulos
Compliance Adviser, Listings Compliance (Melbourne)
ASX Compliance Pty Ltd
525 Collins Street, Melbourne, VIC. 3000

Via email: TradingHaltsMelbourne@asx.com.au

Dear Melissa

**Imugene Limited (ASX: IMU)
TRADING HALT REQUEST**

In accordance with ASX Listing Rule 17.1, Imugene Limited (ASX: IMU) (the **Company**) hereby requests that its securities be placed in a trading halt. The trading halt is requested for the purposes of a planned capital raising to facilitate investment from two new institutional investors.

The Company requests that trading in its securities be halted until after the expected announcement is made or until the market opens on Wednesday, 14 September 2022, whichever is the earlier.

The Company is not aware of any reason why this trading halt request should not be granted.

Please contact me if you require any further information.

Yours sincerely

Phillip Hains
Company Secretary
Imugene Limited